Drug Profile
Risuteganib - Allegro Ophthalmics
Alternative Names: ALG-1001; AM-011; Integrin Peptide Therapy; LuminateLatest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Allegro Ophthalmics
- Developer Allegro Ophthalmics; Hanmi Pharmaceutical
- Class Angiostatic proteins; Anti-inflammatories; Carboxylic acids; Eye disorder therapies; Neuroprotectants; Oligopeptides; Pyrrolidines; Small molecules
- Mechanism of Action Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic macular oedema; Diabetic retinopathy; Dry age-related macular degeneration; Retinal disorders; Wet age-related macular degeneration
- No development reported Retinitis pigmentosa
Most Recent Events
- 26 Sep 2023 National Medical Products Administration approves Clinical Trial Application (CTA) for risuteganib in age-related macular degeneration (Dry AMD)
- 26 Sep 2023 AffaMed Therapeutics plans a phase III trial for age-related macular degeneration in China
- 12 Apr 2023 Allegro Ophthalmics intends to file marketing application